Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiaoliuping Tablet in Stage IV NSCLC Post-chemotherapy
CTR20140636Phase 2Active
- Sponsor
- Jiangxi Sanqi Bioengineering
- Start
- Oct 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xiaoliuping in non-small cell lung cancer (NSCLC), sponsored by Jiangxi Sanqi Bioengineering. Started Oct 2014; status: active.
02
Drugs
xiaoliuping
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20140636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140636.